Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.

Baumann P, Junghanns C, Mandl-Weber S, Strobl S, Oduncu F, Schmidmaier R.

Br J Haematol. 2012 Mar;156(5):633-42. doi: 10.1111/j.1365-2141.2011.08983.x. Epub 2011 Dec 23.

PMID:
22211565
2.

Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.

Baumann P, Schneider L, Mandl-Weber S, Oduncu F, Schmidmaier R.

Anticancer Drugs. 2012 Jan;23(1):131-8. doi: 10.1097/CAD.0b013e32834c8683.

PMID:
21959532
3.

Peripheral T-cell lymphoma with progression to a clonally related, Epstein Barr virus+, cytotoxic aggressive T-cell lymphoma: evidence for secondary EBV infection of an established malignant T-cell clone.

Langer R, Geissinger E, Rüdiger T, von Schilling C, Ott G, Mandl-Weber S, Quintanilla-Martinez L, Fend F.

Am J Surg Pathol. 2010 Sep;34(9):1382-7. doi: 10.1097/PAS.0b013e3181ec577a.

PMID:
20739840
4.

The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.

Mandl-Weber S, Meinel FG, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P.

Br J Haematol. 2010 May;149(4):518-28. doi: 10.1111/j.1365-2141.2010.08124.x. Epub 2010 Mar 1.

PMID:
20201941
5.

The novel, proteasome-independent NF-kappaB inhibitor V1810 induces apoptosis and cell cycle arrest in multiple myeloma and overcomes NF-kappaB-mediated drug resistance.

Meinel FG, Mandl-Weber S, Baumann P, Leban J, Schmidmaier R.

Mol Cancer Ther. 2010 Feb;9(2):300-10. doi: 10.1158/1535-7163.MCT-09-0645. Epub 2010 Feb 2.

6.

Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001.

Baumann P, Hagemeier H, Mandl-Weber S, Franke D, Schmidmaier R.

Anticancer Drugs. 2009 Apr;20(4):259-66. doi: 10.1097/CAD.0b013e328328d18b.

PMID:
19240643
7.

Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells.

Baumann P, Mandl-Weber S, Völkl A, Adam C, Bumeder I, Oduncu F, Schmidmaier R.

Mol Cancer Ther. 2009 Feb;8(2):366-75. doi: 10.1158/1535-7163.MCT-08-0664. Epub 2009 Jan 27.

8.

The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells.

Baumann P, Müller K, Mandl-Weber S, Leban J, Doblhofer R, Ammendola A, Baumgartner R, Oduncu F, Schmidmaier R.

Br J Haematol. 2009 Mar;144(6):875-86. doi: 10.1111/j.1365-2141.2008.07570.x. Epub 2009 Jan 16.

PMID:
19170678
9.

The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.

Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R.

Exp Cell Res. 2009 Feb 1;315(3):485-97. doi: 10.1016/j.yexcr.2008.11.007. Epub 2008 Nov 27.

PMID:
19071109
10.

Alkylating agents induce activation of NFkappaB in multiple myeloma cells.

Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R.

Leuk Res. 2008 Jul;32(7):1144-7. Epub 2008 Feb 20.

PMID:
18083229
11.

Inhibitors of protein kinase C sensitise multiple myeloma cells to common genotoxic drugs.

Baumann P, Armann J, Mandl-Weber S, Grün G, Oduncu F, Schmidmaier R.

Eur J Haematol. 2008 Jan;80(1):37-45. Epub 2007 Nov 19.

PMID:
18028419
13.

Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells.

Baumann P, Mandl-Weber S, Emmerich B, Straka C, Schmidmaier R.

Exp Cell Res. 2007 Oct 1;313(16):3592-603. Epub 2007 Jul 4.

PMID:
17669398
14.

Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways.

Gaul L, Mandl-Weber S, Baumann P, Emmerich B, Schmidmaier R.

J Cancer Res Clin Oncol. 2008 Feb;134(2):245-53. Epub 2007 Jul 25.

PMID:
17653574
15.

Inhibition of adenosine monophosphate-activated protein kinase induces apoptosis in multiple myeloma cells.

Baumann P, Mandl-Weber S, Emmerich B, Straka C, Schmidmaier R.

Anticancer Drugs. 2007 Apr;18(4):405-10.

PMID:
17351392
16.

Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels.

Specht K, Haralambieva E, Bink K, Kremer M, Mandl-Weber S, Koch I, Tomer R, Hofler H, Schuuring E, Kluin PM, Fend F, Quintanilla-Martinez L.

Blood. 2004 Aug 15;104(4):1120-6. Epub 2004 Apr 13.

PMID:
15090460
17.

Discordant bone marrow involvement in diffuse large B-cell lymphoma: comparative molecular analysis reveals a heterogeneous group of disorders.

Kremer M, Spitzer M, Mandl-Weber S, Stecker K, Schmidt B, Höfler H, Quintanilla-Martínez L, Fend F.

Lab Invest. 2003 Jan;83(1):107-14.

18.

Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells.

Mandl-Weber S, Cohen CD, Haslinger B, Kretzler M, Sitter T.

Kidney Int. 2002 Feb;61(2):570-8.

19.
20.

Hyaluronan fragments induce the synthesis of MCP-1 and IL-8 in cultured human peritoneal mesothelial cells.

Haslinger B, Mandl-Weber S, Sellmayer A, Sitter T.

Cell Tissue Res. 2001 Jul;305(1):79-86.

PMID:
11512674
21.
22.

Heat-killed microorganisms induce PAI-1 expression in human peritoneal mesothelial cells: role of interleukin-1alpha.

Mandl-Weber S, Haslinger B, Lederer SR, Sitter T.

Am J Kidney Dis. 2001 Apr;37(4):815-9.

PMID:
11273882
24.

Thrombin upregulates production of plasminogen activator inhibitor type 1 in human peritoneal mesothelial cells.

Mandl-Weber S, Haslinger B, Sitter T.

Perit Dial Int. 1999 Jul-Aug;19(4):319-24.

PMID:
10507812
25.

D-glucose increases the synthesis of tissue-type plasminogen activator (t-PA) in human peritoneal mesothelial cells.

Sitter T, Mandl-Weber S, Wörnle M, Haslinger B, Goedde M, Kooistra T.

Thromb Haemost. 1999 Sep;82(3):1171-6.

PMID:
10494783

Supplemental Content

Loading ...
Support Center